Clinical Practice Session

To Treat or Not to Treat: Medication Toxicity and Clinical Conundrums

November 07, 2019 | 02:00 PM - 04:00 PM

Location: Salon A/B, Walter E. Washington Convention Center

Session Description

This session reviews challenging clinical scenarios for medication prescribing in CKD. Checkpoint inhibitors are efficacious agents that have transformed oncologic care but come with risks of kidney injury. Limited therapeutic options are available to treat pain in CKD, and the legalization of marijuana generates questions about potential risks and benefits. Controversies on the use of direct-acting oral anticoagulants as well as therapies to treat osteoporosis are discussed.

Learning Objective(s)

  • Discuss the risks and benefits of novel therapeutic medications in CKD
  • Describe different opioid and nonopioid options for pain management in CKD

Learning Pathway(s)

  • Chronic Kidney Disease

Moderator(s)

  • Thomas D. Nolin, PharmD, PhD, FASN
  • Tessa Kimberly Novick, MD, MSW

Presentations

  • Toxicity of Checkpoint Inhibitors
    02:00 PM - 02:30 PM
    David E. Leaf, MD, FASN
  • Opiates, Marijuana, and More: Pain Management in CKD
    02:30 PM - 03:00 PM
    David N. Juurlink, MD, PhD
  • Treating Osteoporosis in Advanced CKD: Bisphosphonates and Beyond
    03:00 PM - 03:30 PM
    Susan M. Ott, MD
  • Direct-Acting Oral Anticoagulants in CKD: Are They Safe?
    03:30 PM - 04:00 PM
    Kevin Chan, MD, MS